--- title: "Neboglamine (CR 2249): Dosing & Vendor Prices" description: "Neboglamine (CR 2249): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Neboglamine (CR 2249)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Neboglamine (CR 2249)", "description": "Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010.", "url": "https://www.bodyhackguide.co/compound/neboglamine", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "69.99", "highPrice": "69.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "69.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/neboglamine/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Neboglamine (CR 2249)", "description": "Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010.", "lastReviewed": "2026-09-07T04:47:47.552Z", "url": "https://www.bodyhackguide.co/compound/neboglamine", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Neboglamine (CR 2249)", "alternateName": [ "CR 2249", "CR2249", "(S)-CR 2249", "Nebostinel", "XY-2401", "Neboglamine hydrochloride" ], "description": "Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010.", "activeIngredient": "Neboglamine (CR 2249)", "administrationRoute": "Oral", "mechanismOfAction": "Neboglamine is a positive modulator of the NMDA receptor complex acting on the strychnine-insensitive glycine site pathway, and ChEMBL classifies it as a positive allosteric modulator of the NMDA receptor (ChEMBL1255840). In rat hippocampal slices, (S)-CR 2249 facilitated glycine-mediated reversal of kynurenate antagonism of NMDA-evoked noradrenaline release. It did not change the potency of glycine but increased its efficacy in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperativity with glycine, which points to a distinct allosteric site rather than the glycine site itself (PMID: 9294970). The action is enantioselective: CR 2249 was active in the kynurenate test while its enantiomer CR 2361 was not, in both rat hippocampal slices and human neocortical slices (PMID: 9336311; PMID: 10381808). In rats it also increased hippocampal noradrenaline release (PMID: 9004193).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Neboglamine (CR 2249) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010." } }, { "@type": "Question", "name": "What forms does Neboglamine (CR 2249) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Neboglamine (CR 2249) is available in capsule form." } }, { "@type": "Question", "name": "How much does Neboglamine (CR 2249) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $69.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Neboglamine (CR 2249) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fneboglamine) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Neboglamine (CR 2249) [Where to buy Neboglamine (CR 2249)](/buy/neboglamine) [Neboglamine (CR 2249) coupon codes](/coupons/neboglamine) [Neboglamine (CR 2249) protocol](/protocol/neboglamine) [Alternatives to Neboglamine (CR 2249)](/alternatives-to/neboglamine) [Neboglamine (CR 2249) side effects](/side-effects/neboglamine) 1. [Home](/) 3. [Compounds](/compare) 5. Neboglamine (CR 2249) ![Neboglamine (CR 2249) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Neboglamine (CR 2249) Nootropics Phase 2 Download PDF Also known as: CR 2249, CR2249, (S)-CR 2249, Nebostinel, XY-2401, Neboglamine hydrochloride Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. Half-Life: Not established. No human or animal pharmacokinetic study for neboglamine has been published, and no phase 1 data are available. Route: Oral MW: 256.34 g/mol CAS: 163000-63-3 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Phase 2 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $69.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/neboglamine/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Neboglamine is a positive modulator of the NMDA receptor complex acting on the strychnine-insensitive glycine site pathway, and ChEMBL classifies it as a positive allosteric modulator of the NMDA receptor (ChEMBL1255840). In rat hippocampal slices, (S)-CR 2249 facilitated glycine… Half-Life Not established. No human or animal pharmacokinetic study for neboglamine has been published, and no phase 1 data are available. Routes Oral Potential Benefits Improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice (PMID: 9004193) Increased noradrenaline release in the hippocampus of freely moving rats during microdialysis (PMID: 9004193) Increased the efficacy of glycine at strychnine-insensitive glycine sites coupled to the NMDA receptor in rat hippocampal slices, enantioselectively (PMID: 9294970) Prevented kynurenate antagonism of NMDA-evoked noradrenaline release in slices of human neocortex taken during neurosurgery, while its enantiomer was inactive (PMID: 10381808) Inhibited phencyclidine-induced hyperlocomotion and rearing in rats without changing basal locomotor activity or activating the dorsolateral striatum (PMID: 20045056) ### Overview Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased \[3H\]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010. ### Potential Research Fields NMDA glycine site Schizophrenia Cognitive enhancement Nootropics ## Chemical Information IUPAC Name Not yet available CAS Number 163000-63-3 Molecular Formula C13H24N2O3 Molecular Mass 256.34 g/mol (free acid) ![Neboglamine (CR 2249) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/3074827/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/3074827) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established. No human safety, pharmacokinetic, drug interaction, pregnancy, lactation or organ impairment data have been published. Mechanism-based caution: neboglamine increases NMDA receptor function rather than blocking it, increasing \[3H\]MK-801 binding in a concentration-dependent manner in rat tissue (PMID: 9294970), which is a theoretical excitotoxicity concern for anyone with a seizure disorder, recent stroke or acute brain injury. The compound was investigated as an antipsychotic-like agent in a phencyclidine model (PMID: 20045056), so interaction with psychiatric medication is plausible but has never been studied. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $69.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Neboglamine HCl capsules (60) capsule 60 capsules ● In Stock $69.99 BEST — — [Buy](https://disguisedalpha.com/product/neboglamine/?coupon=reddit) Get Neboglamine (CR 2249) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $69.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Neboglamine (CR 2249). [Sign in](/auth) Current low $69.99 as of Sep 7, 2026 7-day low $69.99 30-day low $69.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Neboglamine (CR 2249) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $69.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for Neboglamine (CR 2249) ](/guides/dosage/neboglamine) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $69.99 [Buy Now](https://disguisedalpha.com/product/neboglamine/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established. No human or animal pharmacokinetic study for neboglamine has been published, and no phase 1 data are available. Molecular Weight 256.34 g/mol (free acid) Administration Oral CAS Number 163000-63-3 Trial Phase Phase 2 0 [Full Dosage Guide](/guides/dosage/neboglamine)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Neboglamine (CR 2249) used for in research? Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased \[3H\]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010. What forms does Neboglamine (CR 2249) come in? Neboglamine (CR 2249) is available in capsule form. How much does Neboglamine (CR 2249) cost? Prices start at $69.99 across 1 verified vendor. How do I compare Neboglamine (CR 2249) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-neboglamine) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋